Quebec bureaucrats refuse to recommend COVID treatment that reduces death by 44%, mechanical ventilation by 50%

Quebec bureaucrats from the INESSS refused to endorse the use of Colchicine, a medication used in the treatment of gout and Behçet’s disease which has shown positive effects in the pre-hospitalization treatment of COVID.

Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email

On January 23, 2021, the Montreal Institute of Cardiology released a groundbreaking study about the effect of colchicine on pre-hospitalized COVID patients. 

In the large sample of 4488 patients, the study found that “that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo”. 

“In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19”, the researchers wrote. 

The INESS’s self-described mission is to “promote clinical excellence and the efficient use of resources in the health and social services sector.” The government institute issues recommendations on various medical treatments and drugs. 

However, according to a leaked report set to come out by Wednesday, the INESS is not going to recommend the use of colchicine in treating pre-hospitalized COVID patients due to a “lack of data”. 

The Montreal Institute of Cardiology’s study was considered a groundbreaking study conducted with exemplary methodology and a substantial sample. The study was conducted with 35 researchers in over 6 countries.

Colchicine is an old and well-known drug. It was first isolated in 1820 by French chemists  P. S. Pelletier and J. B.Caventou. Its side effects are considered minimal.

Countries such as Greece trusted the study and authorized the use of colchicine in treating COVID-19 a day only after the groundbreaking release. 

Health Canada began its review of the drug’s use in COVID patients on January 25. 

The INESS’s refusal to caution the use of colchicine in treating COVID-19 comes with a warning to Quebec physicians to be careful in their use of the treatment. The INESS’s recommendations are not legally binding so physicians will be able to use the treatment as they see fit. 

Support Quality Journalism.

Independent journalism is important now more than ever. The role of journalists in our society is one of watchdogs. One cannot be a watchdog when they are on the government’s payroll. 

Make a donation today and support quality,  independent journalism. 

Share this story:

Share on facebook
Share on twitter
Share on email